Shukra Pharma to Invest Rs 600 Cr in Greater Noida Medical Device Park, Enters Surgical Robotics, Cancer Therapy Tech
Greater Noida: Shukra Pharmaceuticals Ltd. has received a Letter of Intent (LoI) from the Yamuna Expressway Industrial Development Authority (YEIDA) for the allotment of 10 acres of land at the Medical Device Park in Sector 28, Greater Noida, to set up a high-end healthcare manufacturing facility with a planned investment of around Rs 600 crore.
The proposed project will focus on the production of advanced surgical robotics and Boron Neutron Capture Therapy (BNCT) technology, a next-generation cancer treatment modality used for complex and hard-to-treat tumors.
The company said the facility is expected to generate more than 900 direct jobs and nearly 2,000 indirect employment opportunities, significantly boosting the region’s med-tech ecosystem while strengthening India’s capabilities in advanced medical technologies. The initiative is aligned with the government’s vision of positioning India as a global hub for healthcare innovation and medical device manufacturing.
In a parallel development, Shukra Pharmaceuticals has signed a Memorandum of Understanding (MoU) with US-based Borns Medical Robotics Inc. to introduce cutting-edge surgical robotics technology in India. The agreement, formalised at an event held in New Delhi, will enable the launch of the Veer Surgical Robot—an artificial intelligence-enabled surgical platform designed to enhance precision, safety, and consistency of surgical outcomes while improving access to advanced care.
Commenting on the development, Dr. Minakshi Late, CEO and Global Head of Shukra Ltd., said the collaboration is a step towards strengthening India’s self-reliance in healthcare technology. “Our joint venture with Borns is a contribution towards making India Atmanirbhar Bharat. Our efforts will be to make this technology affordable and accessible to patients who deserve it the most, particularly in underserved regions,” she said.
Dr. Alexander T. Teichmann, Chief Medical Officer of Borns Medical Robotics Inc., said the partnership combines Borns’ AI-driven robotics expertise with Shukra’s market reach and manufacturing vision. “Together, we are empowering surgeons, standardising outcomes, and building scalable healthcare infrastructure across India and Asia, ushering in a new era of affordable, accessible, and high-precision surgery,” he said.
Dakshesh Shah, Chairman and Managing Director of Shukra Pharmaceuticals Ltd., reiterated the company’s commitment to democratising advanced healthcare technologies. “Every Indian deserves access to the best healthcare technology. Through this partnership, we are ensuring that cutting-edge robotic surgery is no longer limited to metro cities or premium hospitals,” he said.
Dr. Vivek Bindal, Director and Head of Max Institute of Robotic Surgery, Patparganj, who has been among the early users of the technology, said next-generation robotic platforms like Veer could transform surgical care in India. He noted that features such as single-port surgery, AI-enabled safety systems, and advanced micro-instruments have the potential to significantly improve access to minimally invasive procedures while lowering overall treatment costs.
According to the company, the collaboration will also focus on establishing end-to-end manufacturing and distribution capabilities in India, alongside training programmes for surgeons and the development of supporting clinical infrastructure, laying the foundation for a comprehensive and scalable robotic surgery ecosystem in the country.
